P21
Also known as: P021, Ac-DGGLAG-NH2
Popular For
Neurogenesis, memory, cognitive aging, brain health
Key Facts: P21
- Category
- Cognitive
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical - Development ongoing
- Administration
- Oral (nasal in some studies)
- Typical Dose
- Limited community data available
- Frequency
- See research protocols
- Evidence Level
- Animal Studies
- Duration
- Ongoing supplementation in studies
Mechanism of Action
P21 acts as a CNTF small-molecule peptide mimetic. It enhances neurogenesis in the hippocampus, reduces tau phosphorylation, inhibits neuroinflammation, and improves synaptic plasticity. Designed to be orally bioavailable.
Research Summary
Studies show cognitive improvement in Alzheimer's mouse models. Research demonstrates increased neurogenesis, reduced tau pathology, and improved learning/memory. Being developed for Alzheimer's and age-related cognitive decline.
Dosing Information
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
Limited community data available
See research dosing
See research protocols
Research Dosingⓘ
Scientific studies
Doses from research protocols
Doses from Studies
Research doses vary
Duration
Ongoing supplementation in studies
Administration
Oral (nasal in some studies)
Timing & Administration
Best Time to Take
Morning
Once daily
Food Recommendation
With or without food
Why This Timing?
P21 (BDNF-mimetic) supports neuroplasticity. Morning use may optimize learning and cognitive enhancement.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated
- ●Injection site reactions
- ●Headache
- ●Fatigue
- ●Does NOT cause weight loss like native CNTF
- ●Not FDA approved
References
Related Peptides
Peptides commonly compared with P21 or used in similar applications.
Dihexa
PreclinicalA potent cognitive-enhancing peptide derived from angiotensin IV. Reported to be 10 million times more potent than BDNF at promoting synaptogenesis.
CognitivePE-22-28
PreclinicalA synthetic heptapeptide (7 amino acids) derived from Spadin, a naturally occurring antidepressant peptide. PE-22-28 is a shorter, more stable analog that retains the antidepressant and anxiolytic properties of Spadin. Works by blocking TREK-1 potassium channels in the brain.
CognitiveSelank
Clinical TrialsA synthetic peptide derived from tuftsin, an immunomodulatory peptide. Approved in Russia for anxiety and nootropic effects. Known for anxiolytic properties without sedation.
CognitiveSemax
Clinical TrialsA synthetic peptide derived from ACTH (4-10) fragment with added Pro-Gly-Pro sequence. Approved in Russia for stroke and cognitive enhancement. Known for nootropic and neuroprotective effects.
CognitiveCerebrolysin
Clinical TrialsA mixture of low-molecular-weight neuropeptides derived from pig brain. Approved in many countries for stroke, traumatic brain injury, and dementia.
CognitiveGB-115
Clinical TrialsA dipeptide anxiolytic and nootropic that acts as a CCK-1 (cholecystokinin) receptor antagonist. Developed in Russia with completed Phase 3 trials for anxiety. Users report significant improvements in focus, attention, and ADHD-like symptoms.
CognitiveLooking for a trusted vendor?
Pro members get access to verified vendors with quality standards & exclusive discount codes.
Want updates on P21 research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.